N Engl J Med 375(19):18341844 Marx N, Husain M, Lehrke M, Verma S, Sattar N (2022) GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes
GLP-1 is secreted primarily by L-cells in the distal small intestine and colon
Research consistently shows that a significant proportion of people regain weight after discontinuing GLP-1 injections
Dosing is determined entirely by your licensed provider based on your health history, current medications, and individual goals
Its simultaneous engagement of GLP-1, GIP, and glucagon receptors makes it a valuable reference compound for laboratories investigating multi-pathway receptor biology, energy homeostasis models, and metabolic signaling in preclinical settings
GLP-1 medications provide substantial health advantages beyond weight control